Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1 1

Status

Recruiting 3Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 9Myeloid 7Sarcoma 5Gastrointestinal 5Lymphoid 3Head & Neck 1Dermatologic 1Classical hematology 1

Conditions

Gastrointestinal Stromal Tumors 5Neoplasms 1Digestive System Neoplasms 1

Interventions

Specimen Handling 36Magnetic Resonance Spectroscopy 31Cyclophosphamide 26Doxorubicin 23Biopsy 22pembrolizumab 21Temozolomide 21X-Rays 17Radiotherapy 17Radiation 16Nivolumab 13atezolizumab 12Vincristine 12Phantoms, Imaging 12Irinotecan 12Ifosfamide 12Gemcitabine 12fludarabine 11cabozantinib 10liposomal doxorubicin 8Surgical Procedures, Operative 8Ipilimumab 8Etoposide 8Bevacizumab 8Paclitaxel 7Immunoglobulin G 7Carboplatin 7palbociclib 6olaparib 6fludarabine phosphate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Imatinib Mesylate × Sarcoma × 90 days × Clear all
NCT07171203 2026-05-27

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

University of California, San Diego

Phase 1 Recruiting
18 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT07406633 2026-05-19

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Kumquat Biosciences Inc.

Phase 2 Recruiting
46 enrolled
GastrointestinalSarcoma

Digestive System Neoplasms, Gastrointestinal Stromal Tumors

NCT01742299 2026-05-14

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Novartis

Phase 4 Completed
155 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT07585266 2026-05-13

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

GlaxoSmithKline

Phase 3 Not yet recruiting
800 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05152472 2026-04-24

ATEZOGIST

Centre Leon Berard

Phase 2 Recruiting
110 enrolled
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡